ClinicalTrials.gg
CompletedNCT03814291Updated Apr 17, 2025

A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

A Phase 1 interventional study of IBI302 and IBI302 in Neovascular Age-related Macular Degeneration, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-04-17.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Enrollment
64th of 91
31 · median 62
Started
2019
with 6 others
Phase 1
20 of 106
5 open now
Registered
32nd of 106
by date
Lead sponsor
7 of 106
Innovent Biologics (Suzhou) Co. Ltd.

Among the 106 studies in Macular Degeneration with a site in China, this one is the 64th largest by enrollment of the 91 interventional ones that give a count, is one of 7 that started in 2019, is one of 20 in phase 1, and was the 32nd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This study is designed for single-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single intravitreal injection of IBI302 in patients with wet AMD.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patient ≥ 50 yrs. of age.
  2. Active subfoveal CNV secondary to wet AMD, with lesion size ≤ 12 optic discs in the study eye.
  3. BCVA score of 10-73 letters using ETDRS charts (in 4 meters) in the study eye.
  4. Central macular sub-field thickness according to OCT of at least 250 micron.
  5. Clear stereoscopic fundus photography is obtained while the lens or other media is clear.
  6. Female subjects of childbearing age or male subjects with childbearing age female partner agree to take effective measures from the screening period to 3 months after the end of treatment.
  7. Willing and able to sign form and comply with visit and study procedures per protocol.

Exclusion criteria

Exclusion Criteria:

  1. Presence of other causes of CNV other than wet AMD in the study eye.
  2. Presence of active diabetic retinopathy in the study eye.
  3. Presence of uncontrolled glaucoma in the study eye (defined as IOP≥30mmHg despite the standardized treatment).
  4. Prior retinal detachment in the study eye.
  5. Prior any treatment of following in the study eye:

    1. Anti-VEGF therapy within 6 months prior to screening;
    2. Anti-complement therapy;
    3. Laser photocoagulation;
    4. Photodynamic therapy;
    5. Transpupillary thermotherapy
    6. Intraocular surgery;
    7. Intraocular or periocular injection therapy within 6 months prior to enrollment;
  6. Presence of any non-AMD disease that may affect visual acuity in the study eye
  7. Prior anti-VEGF therapy within 1 month before study drug administration or plan of above anti-VEGF therapy in the non-study eye during the whole study.
  8. Oral steroid drugs within 1 month before study drug administration.
  9. Presence of active intraocular or periocular inflammation or infection.
  10. Diabetic patients have any of the following conditions:

    1. Microvascular and macrovascular complications;
    2. >7.5% when screening;
    3. Receiving more than two oral hypoglycemic agents;
    4. Receiving insulin or GLP-1 receptor agonist;
  11. Hypertension (defined as systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg despite standard treatment);
  12. Presence of any following laboratory abnormality:

    1. \<100×109/L, ≥1.5ULN, APTT≥ 10 seconds more than ;
    2. or AST >2ULN;
    3. Cr or Ur>1.5ULN;
  13. Large or medium surgery, or unhealed surgical incisions, ulcers or fractures within 1 month before study drug administration.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    cohort 1 IBI302 treated with first dose level of IBI302

    Drug: IBI302

  • Experimental
    cohort 2 IBI302 treated with second dose level of IBI302

    Drug: IBI302

  • Experimental
    cohort 3 IBI302 treated with third dose level of IBI302

    Drug: IBI302

  • Experimental
    cohort 4 IBI302 treated with fourth dose level of IBI302

    Drug: IBI302

  • Experimental
    cohort 5 IBI302 treated with fifth dose level of IBI302

    Drug: IBI302

  • Experimental
    cohort 6 IBI302 treated with sixth dose level of IBI302

    Drug: IBI302

Interventions

  • DrugIBI302

    0.05mg/eye;Intraocular injection

  • DrugIBI302

    0.15mg/eye;Intraocular injection

  • DrugIBI302

    0.5mg/eye;Intraocular injection

  • DrugIBI302

    1mg/eye;Intraocular injection

  • DrugIBI302

    2mg/eye;Intraocular injection

  • DrugIBI302

    4mg/eye;Intraocular injection

06

What researchers measure

Primary outcomes

  1. Safety evaluation indicators

    Decreasing of BCVA; b) Changes in intraocular pressure compared with baseline; c) Incidence, relatedness and severity of all adverse events, treatment emergent adverse events and serious adverse events;

    Time frame: Baseline to Day43

Secondary outcomes

  1. Efficacy evaluation indicators

    Changes in central subfield thickness by OCT compared with baseline; b) Changes in CNV area by FA compared with baseline; c) Changes in BCVA compared with baseline.

    Time frame: Baseline to Day43

  2. Immunogenicity evaluation indicators

    Positive rate of anti-drug antibody and neutralizing antibody

    Time frame: Baseline to Day43

  3. The area under the drug-time curve from 0 to time t (AUC0-t)

    Time frame: Baseline to Day43

  4. The area under the curve at the time of 0-infinity (AUC0-∞)

    Time frame: Baseline to Day43

  5. The peak concentration (Cmax)

    Time frame: Baseline to Day43

  6. The peak time (Tmax)

    Time frame: Baseline to Day43

  7. Clearance rate (CL)

    Time frame: Baseline to Day43

  8. Half-life (t1/2)

    Time frame: Baseline to Day43

  9. Free and total VEGF concentration

    Time frame: Baseline to Day43

07

Study locations

1 site
  • Shanghai General Hospital
    Shanghai, Shanghai 200080, China
08

References and documents

Publications

  • Yang S, Li T, Jia H, Gao M, Li Y, Wan X, Huang Z, Li M, Zhai Y, Li X, Yang X, Wang T, Liang J, Gu Q, Luo X, Qian L, Lu S, Liu J, Song Y, Wang F, Sun X, Yu D. Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. Sci Transl Med. 2022 Jun;14(647):eabj2177. doi: 10.1126/scitranslmed.abj2177. Epub 2022 Jun 1. PubMed 35648811 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Mar 2020, 10 months.

Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 10 months is below that.

Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2019
First posted
Jan 24, 2019
StartActual
Apr 15, 2019
Primary completionActual
Mar 5, 2020
CompletionActual
Apr 10, 2020
Last update
Apr 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03814291
Responsible party
Sponsor
First posted
Jan 24, 2019
Start date
Apr 15, 2019
Primary completion
Mar 5, 2020
Completion
Apr 10, 2020
Last update
Apr 17, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI302

Start the discussion